Solid Biosciences Announces Licensing Agreement With Andelyn Biosciences for the Use of Proprietary Next-Generation Capsid AAV-SLB101 (Globe Newswire)
Solid Biosciences Inc., which acquired UF startup AavantiBio, announced a non-exclusive worldwide license and collaboration agreement with Andelyn Biosciences for the use of Solid’s proprietary, next-generation capsid, AAV-SLB101.
Solid Biosciences Awarded Innovation Passport Designation Under the New UK Innovative Licensing and Access Pathway for SGT-003 (BioSpace)
Solid Biosciences Inc., which acquired UF startup AavantiBio, announced that SGT-003, the Company’s investigational gene therapy for Duchenne muscular dystrophy (Duchenne), has been granted an Innovation Passport under the new ILAP.
Tech Tuesday: University of Florida Lab Showcases How Molecular Motors Can Improve Human Life (WCJB TV20)
In this week’s Tech Tuesday, UF Innovate highlights Myosin Therapeutics, a biomedical company developing myosin inhibitors to treat cancer.
Myosin Therapeutics Receives FDA Fast Track Designation for MT-125 in Glioblastoma (PR Newswire)
UF startup Myosin Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to MT-125 for the treatment of glioblastoma (GBM).
With Startup, Researchers Plan To Help Growers Feed More People, Preserve Environment (UF News)
UF startup EZ Ag Innovations, founded by UF researchers Nathan Boyd and Arnold Schumann, is using AI-powered precision-spraying technology to help farmers reduce chemical use, lower costs, and improve sustainability in agriculture.
LightPath Technologies Receives $4.8 Million Purchase Order for Advanced Infrared Camera Systems (PR Newswire)
UF startup LightPath Technologies announced it has received a $4.8 million purchase order with an existing customer related to the supply of advanced infrared camera systems for public safety applications.
iOncologi Secures Foundational U.S. Patent As Landmark Studies Link COVID19 mRNA Vaccines to Improved Survival With Cancer Immunotherapy (Bio Space))
UF startup iOncologi, Inc. announced that USPTO has granted a U.S. patent for a novel method using RNA-based formulations to enhance tumor responsiveness to immune checkpoint inhibitor (ICI) therapy.
Solid Biosciences Announces Licensing Agreement with Kinea Bio for the Use of Proprietary Next-Generation Capsid AAV-SLB101 (Solid Biosciences)
Solid Biosciences Inc., which acquired UF startup AavantiBio, announced a non-exclusive worldwide license and collaboration agreement with Kinea Bio for the use of Solid’s proprietary, next-generation capsid, AAV-SLB101.
Rise Therapeutics Secures New Funding To Advance First-in-Class R-2487 Oral Immune Biomodulator Into Sjogren’s Disease Clinical Testing (Bio Space)
UF startup Rise Therapeutics, a clinical-stage biotechnology company developing a novel class of oral targeted immunotherapies, announced it will be initiating clinical evaluation of R-2487 in SjD.
Atsena Therapeutics Announces Dosing Complete for Adults in Part B of the Phase I/II/III LIGHTHOUSE Trial Evaluating ATSN-201 to Treat X-Linked Retinoschisis (Globe Newswire)
UF startup Atsena Therapeutics announced that dosing is complete in adults enrolled in Part B of the LIGHTHOUSE study, the Phase I/II/III clinical trial evaluating subretinal injection of ATSN-201 for the treatment of X-linked retinoschisis (XLRS).